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This editorial refers to ‘Migratory activity of circulating
progenitor cells and serum SDF-1a predict adverse events in
patients with myocardial infarction’ by O. Fortunato et al.,
pp. 192–200, this issue.
After the oocyte is fertilized, the resulting one-cell zygote gives rise to all
stem cell progenies. During the developmental process, these cells are
necessary to generate all specialized tissues. However, some of them
elude the specification cues and remain quiescent in the adult tissue,
as long as the organism does not suffer from injury, illness, or specific
cell-type depletion. Most adult stem cells are quiescent,1 others, such
as the intestinal stem cells, are very active and feature intense self-
renewal kinetics.2 Nevertheless, when these adult stem cells are awa-
kened by an injury or alerted upon the body’s request, they need to
move on and reach the damaged area using special routs known as cellu-
lar highways (Figure 1). The more advanced the illness, the less the
number of stem cells remaining in stock. Their ability to migrate effect-
ively into damaged or diseased tissues makes the stem cells promising
candidates for cell therapy. Unfortunately, cellular highways can
also be used by cancer (stem-) cells during metastasis, e.g. when
CXCR4-expressing tumour cells migrate into the lung, liver, bone
marrow, and brain, matching high levels of presented SDF-1a.3
Fortunato et al.4 explore the SDF-1a/CXCR4 cellular highway in the
context of cardiac damage, highlighting the correlation betweenSDF-1a
plasma concentration and the migration ability of CXCR4+ circulating
progenitor cells. In a prospective observational study in 172 consecutive
patients with an acute coronary syndrome, of which the majority (83%)
presentedwith ST-elevationmyocardial infarction (MI), the authors cor-
relate functional characteristics of circulating progenitor cells, antigeni-
cally defined as CD34/CD45/CD133/CXCR4pos cells, with a clinical
outcome up to 1 year. When categorizing the study population into
patientswhodeveloped acombined event (death, recurrentMI, or new-
onset heart failure) during the 1-year follow-up and those without an
event, the authors observed reduced spontaneous mobility of these
progenitor cells in an in vitro migration assay. Moreover, they report
somewhat higher serum SDF-1a levels in patients with a subsequent
event, although the significance of the latter is uncertain in view of the
substantial variability in serum levels and the low number of these
patients (n ¼ 30/172 or 13.4%).
Stem cells home towards acutely damaged myocardium following
systemic injection, although the molecular mechanism of this process
is largely unknown. Migration towards damaged tissue is the first step
in stem cell engagement during tissue regeneration. Chemokines and
their receptors dramatically influence the pool of circulating and resi-
dent cardiac progenitor cells, which in turn promote tissue regeneration
and recovery after MI. Stromal cell-derived factor-1a (SDF-1a), stem
cell factor (SCF), hepatocyte growth factor (HGF), and leukaemia inhibi-
tory factor (LIF) are primarily involved in themobilization and homing of
the circulating progenitor cells towards the infarcted heart.5 Several
authors, including Fortunato et al., have confirmed the importance of
the chemokine–chemokine receptor axis SDF-1a/CXCR4 (reviewed
in Cencioni et al.6), which is stimulated during acute cardiac damage. In
fact, many circulating progenitors highly express the chemokine recep-
tors CXCR4, besides c-Met, CD117 (SCF receptor), and leukaemia in-
hibitory factor receptor. Local injection of SCF improves myocardial
homing of systemically delivered progenitor cells.7 Since tissue or
systemic injection of these potent chemokines could determine a
dramatic change on the tissue homeostasis, ex vivo priming of progenitor
cells with SDF-1a before transplantation has been challenged by several
independent groups. Exposure to 100 ng/mL SDF-1a for 30 min
induced proangiogenic phenotype in CD34+ circulating progenitor
cells (PCs),8 resulting in cell migration and differentiation into vascular
cords. Exposure of cardiac mesoangioblasts, vessel-associated stem
cells expressing CD31, CD34, CD44, CD117, and CD146, but not
CD45 and CD133, to SDF-1a improves up to five-fold their homing
to the infarcted heart free wall. The authors also showed that this
treatment improves cardiac regeneration and the recovery of the left
ventricular (LV) wall motion.9 In summary, SDF-1a pre-conditioning
enhances cell survival and differentiation of stem cells during transplant-
ation in infarcted myocardium.6,10
CXCR7 also shows high-affinity binding to SDF-1a and has a more
restricted surface expression, mainly in tumour cells and endothelial
progenitors.11 Although its role in calciummobilization and chemotaxis
is still controversial, it seems that CXCR4 is required for mesenchymal
stemcell (MSC)migration and adhesion,whereasCXCR7 is responsible
forMSCadhesion and survival.12 The fact thatCXCR7 functiondepends
on the cell type, is evident in the migration ability of renal progenitor
cells. Although this phenomenon required the presence of both
CXCR4 and CXCR7, only CXCR7 seems to be essential in renal pro-
genitors in order to adhere to the endothelial cells.13 It is interesting
to note that CXCR7 has been shown to internalize and degrade
SDF-1 as a ligand scavenger,14 which could modulate the functioning
of CXCR4 in PCs of Fortunato et al. clinical study.
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In this study, Fortunato et al. have performed a careful and detailed
analysis of the migratory response of circulating progenitor cells to the
SDF-1a gradient. Similar to the colony-forming capacityofmononuclear
bonemarrowcells, migratory capacity of circulation PChas been recog-
nized asoneof thekey factors thatmaymodulate thepositiveornegative
effects of cell-based therapies for acute MI (AMI).5 However, the rele-
vance of SDF-1a to cell migration can be indicated from a different
angle as pointed out by Fortunato et al., discovering an intriguing
aspect concerning the SDF-1a/CXCR4 axis. In fact, they hypothesize
that an impaired functionality of CD34/CD45/CD133/CXCR4pos PCs
might directly reflect a reduced cardiac reparative response in AMI
patients. The foundation of the authors’ hypothesis is to establish a
link between functionally impaired circulating stem cells and adverse
events in AMI patients. They first determined whether abundance and
migratory activity of PCs’ prognosticate re-infarction, new-onset heart
failure, and all-causemortality in patientswith AMI. Then they evaluated
the association between cytokines and clinical outcomes, focusing
in particular on the serum levels of SDF-1a, b-FGF, IGF, VEGF-A,
PDGF-BB, troponin I, and CPK-MB. Their concept, however, has
broad implications as a potential intermediate step between a clinical
observation and future therapeutic approaches to modulate the
amount of circulating cytokines and PCs. Recently, the role of SDF-1a
in mobilizing stem cells in combination with endothelial progenitor
cell (EPC) transplantation has been investigated in a regenerative strat-
egy for MI therapy in a murine ischaemia–reperfusion model.15 Bone
marrow was destroyed and restored with the use of green fluorescent
protein (GFP)-labelled donor cells, before inducing myocardial ischae-
mia. After reperfusion, EPCs were injected directly into the border
zones of the infarcted areas and challengedwith anti-SDF-1a antibodies.
Histological analysis revealed that EPC and anti-SDF-1a administration
Figure 1 SDF-1a/CXCR4 cellular highway. Chemokines control cellular traffic by directing cells that express certain chemokine receptors to specific
locations where their ligands are abundant. Besides PCs (circulating progenitor cells) other stem cell types could be recruited in specific cellular highways
according to their chemokine receptor expression. ESCs, embryonic stem cells; iPSCs, induced pluripotent stem cells; MABs, mesoangioblasts; MADS,
multipotent adipose-derived stem cells.
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diminished the amount of GFP-positive bone marrow cells in the heart.
The authors of this study concluded that transplanted EPCs, as well as
SDF-1a, are key factors in guiding endogenous bone marrow cells into
the infarctedmyocardium.Anti-SDF-1a treatment results in a significant
decreased left ventricular function, but does not alter the neovascular-
ization of infarcted areas. This preclinical study clearly indicates that
SDF-1a and EPCs are strictly connected to the homeostasis of bone
marrow cells and their perturbation implicates important changes in
cell mobilization and clinical outcomes. Intriguingly, Fortunato et al.
found that AMI patients that underwent percutaneous coronary inter-
vention (PCI) present circulating PCs that are insensitive to SDF-1a
stimulation, as documented by in vitromigration assay. This reduced sen-
sitivity toSDF-1amayreflect an impairedrecruitmentof curative cells to
the infarcted heart, leading to a defective recovery and a higher risk of
late complications.
To translate these novel mechanistic insights into innovative thera-
peutic strategies, JVS-100, a DNA plasmid encoding human SDF-1a,
has been recently tested in a phase 1, dose-escalation study with
12-month follow-up in subjects with ischaemic cardiomyopathy.16
This promising study suggests that the overexpression of SDF-1a
improvesheart failure symptoms inpatientswith ischaemiccardiomyop-
athy.Thus, thepotential regenerative/reparativemechanismof activated
SDF-1a/CXCR4 axis is not limited in stem-cell mobilization, but it could
be related to other biological phenomena, i.e. neovascularization,
cardio-protection, cardiomyocyte cell cycle induction.
One of the significantmerits of the present study by Fortunato et al. is
the recognition of this pathway as a putative predictor of adverse events
in AMI patients at 1-year follow-up.
The role of SDF-1a in stem-cell migration seems now well estab-
lished, emphasizing the pivotal role of homeostatic CXCR4 receptors
in this process.
However, in view of the relatively small sample size and the low event
rate in this low-risk AMI population receiving contemporary
state-of-the-art reperfusion therapy, additional data are required in
large-size follow-up studies. Obviously, we need to better understand
themolecularmechanisms of homeostatic chemokines on stem-cell mi-
gration and other cell functions before we will be able to prevent fatal
accidents on these cellular highways. In this regard, it has been recently
shown that eNOS inhibition enhances cardiac fibrosis by activating
SDF-1a/CXCR4 axis in cardiac fibroblasts.17 On the other hand,
ongoing strategies to enhanceNO bioavailability in other PCs have aug-
mented their repair potential.18Moreover, chemokines are also likely to
directly determine the viability and growth of stem cells, extending their
mode of action beyond drivers of stem cell traffic on cellular highways. It
is very likely that chemokine-receptor axes play a prominent role in the
molecular signature of stem cells and exert significant prognostic
information.
Taken together, this is an exciting area of translational science in need
of additional learning. Novel predictors of early adverse events are of
great value in our efforts to develop better therapies for high-risk
patients, and may eventually become useful biomarkers to lead the
way towards innovative treatments. The time is now right for larger
cohort studies to assess thepredictive valueof these intriguing biological
biomarkers and pave theway for future targeted cell-based intervention
studies.
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